Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN U F versus KETOZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN U F versus KETOZOLE.
FULVICIN-U/F vs KETOZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of fungal cell mitosis by binding to microtubules, disrupting spindle formation and nuclear division.
Ketoconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This leads to increased membrane permeability and cell death.
125 mg orally once daily with a high-fat meal for 7 days, then 125 mg every other day for 7 days (total 13 doses).
200 mg orally once daily with food.
None Documented
None Documented
Terminal half-life approximately 9.5 hours; may be prolonged in liver disease.
Terminal elimination half-life is approximately 2 hours (range 1.5–3.5 hours). Clinically, duration of antifungal effect extends beyond plasma half-life due to persistent tissue levels.
Primarily hepatic metabolism; <1% excreted unchanged in urine; metabolites excreted in bile and feces.
Primarily hepatic metabolism; renal excretion of unchanged drug <1%. Biliary/fecal excretion accounts for ~20-35% of metabolites.
Category C
Category C
Antifungal
Antifungal